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Implication for health policy/practice/research/medical education:
The present study showed that silymarin mitigates DIC-induced liver toxicity through inhibition of inflammation and oxidative 
stress in male rats. After clinical trials, silymarin may be used with DIC as a complementary drug for decreasing the toxicity of 
DIC.
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Introduction: Diclofenac (DIC) is one of the compounds derived from acetic acid which is 
known for its anti-inflammatory and analgesic attributes. Silymarin is a flavonoid compound 
which is derivate from Silybum marianum seeds. This research was done to assess the protective 
role of silymarin against liver toxicity induced by DIC in male rats. 
Methods: Randomly, 40 male Wistar rats were assigned into five groups as follows: Group 1: 
control group, Group 2: DIC-only treated (50 mg/kg, i.p), Group 3: silymarin-only treated (200 
mg/kg, p.o); Groups 4 and 5: DIC (50 mg/kg, i.p) plus silymarin (100 mg/kg and 200 mg/kg, p.o, 
respectively) treated. Various biochemical, molecular, and histological parameters were evaluated 
in serum and tissue. 
Results: In the DIC-only treated group, the levels of liver glutathione peroxidase (GPx), superoxide 
dismutase (SOD), intracellular glutathione (GSH) and catalase (CAT) significantly diminished and 
the levels of total bilirubin, alkaline phosphatase (ALP), nitrite, alanine aminotransferase (ALT), 
malondialdehyde (MDA), serum tumor necrosis factor-α (TNF-α), aspartate aminotransferase 
(AST), and TNF-α gene expression were remarkably elevated relative to control animals. In other 
hands, treatment with silymarin caused a noticeable elevation in GPx, SOD, GSH, CAT and a 
remarkable reduction in levels of total bilirubin, ALP, nitrite content, ALT, MDA, serum TNF-α, 
AST and TNF-α gene expression relative to DIC-only treated group. Histopathological injuries 
were also improved by silymarin administration. 
Conclusion: The results confirm that silymarin has an ameliorative effect on liver toxicity induced 
by DIC and oxidative stress in male rats.
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A B S T R A C T
Introduction
Drug induced liver toxicity is one of the main worries for 
pharmaceutical industry and physicians (1). Non-steroidal 
anti-inflammatory drugs have anti-inflammatory and 
analgesic properties that are widely prescribed and 
some of them cause liver toxicity (2,3). Diclofenac (DIC) 
belongs to Non-steroidal anti-inflammatory drug family 
and it is one of the compounds derived from phenyl 
acetic acid but liver toxicity is one of the main concerns 
for this drug (4). The mechanism of liver toxicity induced 
by DIC has been partly associated to mitochondrial 
damage (5,6), disruption of antioxidant defense system 
(7), change in the integrity of covalent protein by reactive 
metabolites (8), and the mechanisms mediated by the 
immune system (9). DIC is listed under FDA black box 
warning for cardiovascular toxicity and liver toxicity with 
mitochondrial liabilities (10). Therefore, any therapeutic 
agent which can suppress any of the pathological pathways 
activated by DIC might be used to prevent or inverse its 
toxic action. 
Silymarin is a flavonoid compound which is derivate 
from Silybum marianum seeds. It is a combination 
of silydianine, silychristine, silibinin and isosilybinin 
(11). Previous studies have shown that silymarin has 
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antioxidant and anti-inflammatory properties (12,13). 
This research was aimed to assess the noxious effect of 
DIC intoxication on the liver through serum biochemical 
markers, oxidative stress, gene expression of tumor 
necrosis factor-α (TNF-α), histological alterations and 
protective role of silymarin on DIC intoxication in rats.
Materials and Methods 
Chemicals
2-thiobarbituric acid, sodium acetate, and H2O2 were 
prepared from Merck company (Darmstadt, Germany). 
Silymarin, 5,5-dithiobis-2-nitrobenzoic acid, griess 
reagent, GSH, nitro blue tetrazolium and TPTZ 
(2,4,6-tripyridyl-s-triazine) were purchased from Sigma 
(St. Louis, MO). SYBR Green Real Time-PCR Master Mix 
was provided from Qiagen Co. (Dusseldorf, Germany). 
Total bilirubin, alkaline phosphatase (ALP), aspartate 
aminotransferase (AST) and alanine aminotransferase 
(ALT) were evaluated using kits of Pars Azmun co 
(Tehran, Iran). All other chemicals which employed in 
this study were of analytical grade.
Animals
Forty male Wistar rats weighting around 220 g (6–8 week 
old) were applied for this research. The experimental rats 
were obtained from Jondishapour University (Ahwaz, 
Iran). The rats were kept under 25°C ambient temperature, 
50% relative humidity and a dark– light cycle (12 hours) 
and were allowed free access to water and standard diet. 
All methods were confirmed by the Ethics Committee 
of Shahrekord University of Medical Sciences Ethics 
Committee, Shahrekord, Iran (Ethic number IR.SKUMS. 
REC.94.146).
Experimental design
Randomly, 40 male Wistar rats were assigned into five 
groups each comprising of eight animals and treated for 
5 days. Group 1 (control group) was treated with normal 
saline (1 mL/kg, i.p.). Group 2 received DIC only (50 mg/
kg bw, i.p.) (14). Group 3 received silymarin only (200 
mg/kg). Group 4, 5 received DIC (50 mg/kg bw, i.p.) plus 
silymarin (100, 200 mg/kg bw, p.o, respectively) (15-17). 
At the end of our study, fasted rats were killed under 
mild chloroform anesthesia. Whole blood specimens 
were gathered by cardiac puncture procedure to obtain 
serum and plasma. Also, liver tissue was removed for 
determining liver catalase (CAT), superoxide dismutase 
(SOD), and glutathione peroxidase (GPx) activities, nitrite 
content, lipid peroxidation, gene expression of TNF-α, 
and histological studies. 
Biochemical analysis
Serum biochemical markers such as total bilirubin, ALP, 
AST and ALT contents were measured by an enzymatic 
method (Pars Azmun kit, Pars Azmun Co., Tehran, Iran) 
using autoanalyzer (BT 3000, Biotecnica, Cergy Pontoise 
Cedex, France). 
Determination of ferric reducing/antioxidant power 
(FRAP) 
Ferric reducing/antioxidant power was determined by 
Heidarian and Soofiniya procedure (18). Brifly, plasma 
was mixed with FRAP reagent (composed of: 25 ml acetate 
buffer, 2.5 ml TPTZ solution and 2.5 ml FeCl3) then 10 
minutes incubated at 37 centigrade degree and optical 
density of blue color was measured at 593 nm. FeSO4 was 
used as a standard of FRAP assay at a concentration range 
between 100 and 1000 μM. The results are reported as 
μmol/L.
Determination of nitrite content
Content of nitrite was evaluated using a griess reagent 
(19). Briefly, liver supernatant was blended with griess 
reagent (composed of: 0.1% N-(1-naphthyl) ethylene 
diamine, 1.0% sulfanilamide and 2.5% orthophosphoric 
acid) then, 30 minutes incubated at 37 centigrade degree 
and light absorbance was measured at 548 nm. Content of 
nitrite was assessed using standard curve of sodium nitrite 
and was reported as μM/mg tissue.
Determination of lipid peroxidation
MDA contents in rat liver and serum were determined by 
the TBA reactive substance test as described previously 
(18). Briefly, plasma or supernatant was mixed with sodium 
dodecyl sulfate (8.1%) and TBA/buffer (composed of: of 
0.53% thiobarbituric acid in 20% acetic acid as adjusted 
to pH 3.5 with NaOH) then, 60 minutes incubated at 95 
centigrade degree. The reaction was stopped by placing 
tubes on ice followed by centrifugation at 4000 rpm for 10 
minutes. The optical density of pink color was measured 
at 532 nm. 1, 1, 3, 3-tetraethoxypropane was used as a 
standard of MDA assay. The measurements were done in 
duplicates and the results were expressed in μmol/L.
Determination of intracellular GSH levels
Intracellular GSH contents were determined using of 
Ellman method (20). In this procedure 5,5-dithiobis-2-
nitrobenzoic acid reacts with GSH and the optical density 
has a peak value at 410 nm. Data were reported as μmol/g 
tissue.
Tissue GPx activity
The activity of GPx was assayed by determining the 
reduction of GSH level after adding the sample in the 
presence of H2O2 and NaN3 (21).
Determination of tissue CAT and SOD activities
The liver CAT activity of experimental groups was 
measured as described previously by Heidarian et al 
(22). Briefly, H2O2 solution (composed of: 10 mmol H2O2 
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in 50 mM phosphate buffer, pH 7.4), and homogenate 
was pipetted into a cuvette. The reduction of H2O2 was 
followed at a wave length of 240 nm for 2 minutes. The 
activity of liver SOD was evaluated using the inhibition 
of the NBT photo chemical reaction at 560 nm (23). All 
total protein samples were assessed using the method of 
Bradford (24).
Determination of serum TNF-α
Serum TNF-α was assessed using the ELISA assay kit (BT-
Laboratory, China) according to the procedure provided 
by the manufacturer.
Determination of TNF-α gene expression
The mRNA was extracted using the BIOZOL kit 
reagent (Bioer, China) according to the instructions. 
Quality and quantity of total RNA were measured by 
absorbance of 260/280 nm using a spectrophotometer 
by the Nanodrop2000 (Thermo USA). cDNA 
measurement was done by the PrimeScriptTM reagent 
kit (Takara Bio Inc. Japan) and in accordance with 
the instructions. Then, cDNA amplified according 
to RT-qPCR and using SYBR® Green PCR Master 
Mix in the presence of specific primers for TNF-a 
(forward: 5’-CTGGCGTGTTCATCCGTTC-3’, reverse: 
5’-GGCTCTGAGGAGTAGACGATAA-3’) and β-actin 
(forward: 5’-CTTCTACAATGAGCTGCGTGTGGCC-3’, 
reverse: 5’-GGAGCAATGATCTTGATCTTCATGG-3’). 
Primers after design with Oligo 7.0 software was 
approved using Blast-Nucleotide (NCBI). PCR carried 
out in primary denaturation at 95°C for 10 minutes. RT-q 
PCR was performed in 40 cycles (including secondary 
denaturation at 15 seconds at 95°C, 20 seconds at 60°C 
for annealing, 25 seconds for 72°C for extension). β-actin 
gene was used as an internal control gene to control the 
expression of mRNA. Also, ΔΔCT method was used for 
the analysis of gene expression.
Histopathological study
A segment of each liver was fixed in 10% formalin 
solution. All samples were embedded in paraffin and 5 µm 
thickness sections were prepared. Then, the slices stained 
with hematoxylin–eosin (H & E) for histopathological 
observation (25,26). 
Statistical analysis
One-way analysis of variance (ANOVA) was used for data 
analysis using SPSS software (Statistical Package for the 
Social Sciences, version 20.0, SPSS Inc, Chicago, IL). All 
data were expressed as mean ± SD. Also, ΔΔCT method 
was used for the analysis of TNF-α gene expression. Mean 
values of the groups were compared using the Tukey post 
hoc test. P < 0.05 was statistically considered significant.
Results
Effects of silymarin on serum ALT, AST, ALP and total 
bilirubin
Table 1 shows the effects of DIC and silymarin on total 
bilirubin, ALP, AST and ALT in serum. Injection of 
DIC in DIC-only treated group led to a noticeable 
elevation (P < 0.05) in serum ALT, AST, ALP and total 
bilirubin relative to control animals (Table 1). However, 
administration of silymarin led to noticeable decline 
(P < 0.05) in ALT, AST, ALP and total bilirubin in animals 
exposed to DIC.
Effects of silymarin on plasma FRAP, Nitrite content and 
MDA levels
The effects of silymarin on MDA levels, Nitrite content 
and plasma FRAP are shown in Table 2. In the DIC-only 
treated group, injection of DIC resulted in a remarkable 
decrease (P < 0.05) in plasma FRAP and a noticeable 
increase in nitrite content, liver MDA and serum MDA 
contents relative to control animals. Treatment with 
silymarin caused a noticeable elevation (P < 0.05) in 
plasma antioxidant capacity (FRAP) and a noticeable 
decrease (P < 0.05) in nitrite content, liver MDA and 
serum MDA contents in animals exposed to DIC. 
Effects of silymarin on CAT activity, SOD activity, GPx 
activity and GSH level
Table 3 shows that injection of DIC led to a noticeable 
reduction (P < 0.05) in hepatic CAT and SOD activities in 
DIC-only treated group relative to the control animals. A 
considerable elevation (P < 0.05) in hepatic SOD and CAT 
activities was observed after treatment with silymarin in 
Table 1. Effects of silymarin on serum ALT, AST, ALP and total bilirubin in the experimental groups
Parameters Group 1 Group 2 Group 3 Group 4 Group 5
ALT (U/L) 26.13 ± 5.73 81.02 ± 7.95a 25.32 ± 6.12b 38.09 ± 4.53abc 28.26 ± 3.06bd
AST (U/L) 50.66 ± 2.28 110.4 ± 10.42a 49.35 ± 3.12b 62.12 ± 3.62abc 52.76 ± 2.85bd
ALP (U/L) 139.4 ± 4.75 428.1 ± 7.25a 140.2 ± 4.38b 252.32 ± 5.85abc 146.21 ± 5.3bd
Total bilirubin (mg/dL) 0.85 ± 0.02 2.4 ± 0.05a 0.83± 0.03b 1.02 ± 0.04abc 0.87 ± .03bd
Data are expressed as mean ± SEM (n=8) and analyzed by one-way ANOVA followed by Tukey post hoc test. Group 1: control animals; Group 2: DIC-only 
treated animals; Group3: silymarin-only treated animals (200 mg/kg); Groups 4 and 5: the animals were treated by DIC plus silymarin at doses of 100 
mg/kg and 200 mg/kg, respectively.  a P < 0.05 versus control animals (group 1), b P < 0.05 versus DIC-only treated animals (group 2), c P < 0.05 versus 
silymarin-only treated animals (group 3), d P < 0.05 versus animals treated by DIC plus silymarin at dose of 100 mg/kg (group 4).
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animals exposed to DIC. Table 3 also shows a remarkable 
decrease (P < 0.05) in liver GPx activity in the DIC-only 
treated group compared to the control animals. However, 
administration of silymarin at doses of 100 and 200 mg/
kg remarkably elevated liver GPx activity in DIC exposed 
rats. Also injection of DIC in DIC-only treated group led 
to a noticeable reduction (P < 0.05) in liver GSH relative to 
the control group (Table 3). Nevertheless, treatment with 
silymarin at doses of 100 and 200 mg/kg let to remarkable 
elevation (P < 0.05) in liver GSH in rats exposed to DIC.
The effects of silymarin on serum and gene expression of 
TNF-α
Figure 1 shows the effects of silymarin on level of serum 
TNF-α and TNF-α gene expression. DIC injection in DIC-
only treated group led to a remarkable increase (P < 0.05) in 
serum TNF-α level and TNF-α gene expression compared 
to the control group. Treatment with silymarin led to a 
noticeable reduction (P < 0.05) in level of serum TNF-α 
and TNF-α gene expression in DIC exposed animals. A 
remarkable change (P < 0.05) was seen in gene expression 
and serum level TNF-α in the group treated with silymarin 
at dose of 100 mg/kg in comparison with the group treated 
with silymarin at dose of 200 mg/kg.
Histopathological findings
The histopathological results are demonstrated in Figure 
2. The microscopic examination demonstrated normal 
structures of liver tissue from a control rat in the control 
group (Figure 2A). Injection of DIC in DIC-only treated 
Table 2. Effects of silymarin on FRAP, Nitrite content and MDA levels in the experimental groups
Parameters Group 1 Group 2 Group 3 Group 4 Group 5
Serum FRAP (μM) 526.27 ± 31.22 374.26 ± 27.41a 618.67 ± 50.21ab 498± 37.64bc 612.25 ± 48.66abd
Nitrite content (μM/mg tissue) 5.63 ± 0.21 13.32 ± 0.89a 5.51± 0.32b 7.48 ± 0.38abc 5.56 ± 0.28bd
Serum MDA (nmol/L) 8.43 ± 2.52 19.68 ± 3.18a 7.96 ± 2.39b 13.65 ± 2.15abc 8.17 ± 1.87bd
Liver MDA (nmol/mg protein) 1.91 ± 0.71 5.51± 1.15a 1.80 ± 0.67b 3.56 ± 0.76abc 1.87 ± 0.58bd
FRAP (ferric reducing/antioxidant power), MDA (malondialdehyde). 
Data are expressed as mean ± SEM (n=8) and analyzed by one-way ANOVA followed by Tukey post hoc test. Group 1: control animals; Group 2: DIC-only 
treated animals; Group3: silymarin-only treated animals (200 mg/kg); Groups 4 and 5: the animals were treated by DIC plus silymarin at doses of 100 
mg/kg and 200 mg/kg, respectively. a P < 0.05 versus control animals (group 1), b P < 0.05 versus DIC-only treated animals (group 2), c P < 0.05 versus 
silymarin-only treated animals (group 3), d P < 0.05 versus animals treated by DIC plus silymarin at dose of 100 mg/kg (group 4).
Table 3. Effects of silymarin on CAT activity, SOD activity, GPx activity and GSH level in the experimental groups
Parameters Group 1 Group 2 Group 3 Group 4 Group 5
CAT (U/mg protein) 165.32± 14.32 55.27±6.12a 169.18 ± 13.21b 112.87±9.76abc 167±15.13bd
SOD (U/mg protein) 46.32± 4.12 27.61±2.89a 48.96 ± 5.11b 37.21±3.13abc 47.43±3.98bd
GPx (U/mg protein) 26.34 ± 0.89 20.12 ± 0.76a 26.94 ± 0.98b 23.12 ± 0.61abc 25.86 ± 1.07bd
GSH (μmol/g tissue) 12.89 ± 0.11 5.01 ± 0.09a 13.11 ± 0.19b 8.86 ± 0.09abc 13.02 ± 0.17bd 
CAT (catalase), SOD (superoxide dismutase), GPx (glutathione peroxidase), GSH (reduced form of glutathione). Data are expressed as mean ± SEM (n=8) 
and analyzed by one-way ANOVA followed by Tukey post hoc test. Group 1: control animals; Group 2: DIC-only treated animals; Group3: silymarin-only 
treated animals (200 mg/kg); Groups 4 and 5: the animals were treated by DIC plus silymarin at doses of 100 mg/kg and 200mg/kg, respectively. aP < 
0.05 versus control animals (group 1), bP < 0.05 versus DIC-only treated animals (Group 2 ), cP < 0.05 versus silymarin-only treated animals (group 3), 
dP < 0.05 versus animals treated by DIC plus silymarin at dose of 100 mg/kg (group 4).
Figure 1. Effects of silymarin on serum tumor necrosis factor-α (TNF-α) and expression of TNF-α in the experimental groups. Each value represents the 
mean ± SEM of eight rats. Group 1: control animals; Group 2: DIC-only treated animals; Group3: silymarin-only treated animals (200 mg/kg); Groups 4 and 
5: the animals were treated by DIC plus silymarin at doses of 100 mg/kg and 200 mg/kg, respectively. ap < 0.05 versus control animals (group 1), bp < 0.05 
versus DIC-only treated animals (group 2), cp < 0.05 versus silymarin-only treated animals (group 3), dp < 0.05 versus animals treated by DIC plus silymarin 
at dose of 100 mg/kg (group 4).
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group demonstrated mononuclear cells infiltration and 
histological changes compared to the control group 
that reflected liver toxicity (Figure 2B). Treatment with 
silymarin led to a noticeable reduction in inflammatory 
cell infiltration in groups exposed to DIC (Figure 2D&E). 
The decrease of inflammatory cells in treated group with 
silymarin at dose of 200 mg/kg was more than treated 
group with silymarin at dose of 100 mg/kg.
Discussion 
Our findings showed that DIC at 50 mg/kg induced liver 
toxicity in male rats and silymarin prevented its hepatotoxic 
effects. The release of specific enzymes such as AST, ALT, 
and ALP into circulatory system is one of the most sensitive 
signs of liver damage. In our study noticeable elevation 
was seen in the contents of total bilirubin, AST, ALT and 
ALT in DIC-only treated group (Table 1) compared to the 
control animals which approved the liver toxicity potential 
of DIC. These results are in agreement with prior reports 
(5,14,27). In this study treatment with silymarin at doses 
of 100 and 200 mg/kg reversed changes induced by DIC in 
the contents of ALT and AST. This indicates that silymarin 
protected the structural integrity of liver cell membranes 
and eventually inhibited the leakage of these enzymes 
into circulatory system. The elevation in the contents of 
total bilirubin and ALP observed in the DIC-only treated 
animals is a marker of cholestasis in obstructive jaundice 
(28). Cysteinyl leukotrienes play an important role in 
inflammatory responses and the escalation of cholestasis 
in obstructive jaundice (28). In this research, reduction 
in levels of total bilirubin and ALP in silymarin treated 
groups may be linked with its anti-inflammatory and 
antioxidant properties. There seems to be difference in 
the effect of silymarin at doses of 100 and 200 mg/kg on 
these markers. Therefore, it can be said that the effect of 
silymarin on these biochemical markers is dose sensitive. 
Histopathological studies of DIC-only treated group 
depicted increased lymphocyte infiltration and apoptotic 
changes, which show liver toxicity induced by DIC in rats 
according to prior investigations (14, 27). Remarkable 
recovery towards normal liver histopathology in silymarin 
administrated groups further supported the protective 
effect of silymarin on DIC-induced hepatotoxicity.
MDA is a reliable marker for lipid peroxidation (LPO). 
Increased LPO by DIC as one of the signs for oxidative 
stress published previously by various studies (14, 27, 
29). In this research, DIC-induced liver toxicity led to a 
noticeable elevation in the content of MDA in serum and 
hepatic tissue relative to the control animals that is in line 
with the prior published investigations (5,30,31). On the 
other hand, administration of silymarin not only increased 
the FRAP content in plasma but also decreased the MDA 
level in the serum and hepatic tissue in rats exposed to 
DIC. The elevated FRAP content and decreased LPO level 
in silymarin treated groups might be due to direct increase 
in GSH content or due to its free radical scavenging 
property. 
Increase in level of nitrite in DIC-only treated rats 
indicated the effect of NO in liver toxicity induced by DIC. 
Our results are in line with the prior studies that have 
shown NO creates important role in chemical toxicity (32, 
33). Remarkable reduction of nitrite content in silymarin 
treated groups suggested that this antioxidant offered liver 
protection in DIC exposed rats by reduce the NO content 
and nitrosative stress. 
Intracellular glutathione (GSH), the principal 
endogenous antioxidant, creates a critical role in defense 
of cell on damage induced by oxidative stress. Both in 
vivo and in vitro studies have shown the effect of GSH 
depletion in oxidative stress induced by DIC in various 
model systems (27,30,34). In our research, DIC-induced 
liver toxicity led to a noticeable reduction in the content 
of GSH in liver tissues relative to the control animals. 
On the other hand, a noticeable recovery of GSH level 
was observed in silymarin administrated groups. GSH 
recovery may be due to the ability of silymarin to reduce 
oxidative stress or to increase the GSH content directly. 
In order to survey the role of silymarin on metabolism of 
Figure 2. Effects of Silymarin on the liver histology of experimental groups. (A) Control animals with normal structure; (B) DIC-only treated animals show 
lymphocyte infiltration (the black arrows); (C) silymarin-only treated animals (200 mg/kg) ;(D) DIC-injected animals supplemented with silymarin (100 mg/kg); 
(D) DIC-injected animals supplemented with silymarin (200 mg/kg).
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GSH, our study assessed its role on GPx as GSH metabolizing 
enzyme. GPx simplifies peroxides neutralization via react 
with GSH and leading to increased contents of GSSG 
(oxidized glutathione), that is then reduced by glutathione 
reductase return to the GSH thereby maintaining the 
antioxidant content. DIC-induced changes in activity of 
GPx have been indicated previously (14,30). In our study, 
DIC-induced increase in GPx activity (Table 3) may be 
due to the defense mechanism against elevated LPO and 
noticeable reduction in GPx activity in the treated groups 
with silymarin can be due to the decrease levels of LPO or 
oxidative stress.
Previous investigations have indicated that injection of 
DIC causes a remarkable reduction in CAT and SOD in 
animals (5,14,30). In our investigation, injection of DIC 
caused the reduction in activities of CAT and SOD. On the 
other hand, treatment with silymarin remarkably restored 
these alterations of enzymatic activities in animals. The 
decrease in SOD and CAT activities in silymarin treated 
rats could be due to antioxidant properties of silymarin.
TNF-α is a cytokine which releases in the inflammatory 
conditions and migration of macrophages. TNF-α leads 
to oxidative stress which in turn increases the liver 
cells damage (35). Previous researches have shown that 
injection of DIC led to remarkable elevate in serum level of 
TNF-α and its gene expression in hepatic tissue (5,14,30). 
The result of our study showed that liver TNF-α gene 
expression and serum TNF-α content elevated remarkably 
in the DIC-only treated group relative to the control 
animals. In our investigation, liver TNF-α gene expression 
and serum TNF-α level significantly decreased in the 
silymarin-treated rats. Thus, the decrease in TNF-α serum 
content and expression of TNF-α is another obvious, at 
least partly, which confirms the liver protective role of 
silymarin due to its antioxidant properties.
Conclusion 
Our study indicates that silymarin has protective effect 
against DIC-induced liver toxicity in rats. Also, silymarin 
as a natural component due to its anti-inflammatory 
and antioxidant properties may lead to improvement in 
complications of DIC consumption such as liver toxicity.
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